Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YoY Growth of 21% - 30% 1,2 Announces New $250 million Accelerated Share Repurchase Conference Call Scheduled Today at 5:30am PT/8:30am ET Exhibit 99.1 Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance Reports Pr ...